Scandinavian ChemoTech AB Class B (SE:CMOTEC.B)
:CMOTEC.B
Want to see SE:CMOTEC.B full AI Analyst Report?
Top Page
Scandinavian ChemoTech AB Class B
(CMOTEC.B)
Select Model
Select Model
Rating:53Neutral
Price Target:
kr4.00
▼(-16.49% Downside)
Action:ReiteratedDate:04/16/26
The score is held back primarily by weak profitability, negative gross margin, and continued cash burn with equity erosion, despite improved revenue growth and reduced losses. Technicals are mildly supportive (neutral-to-positive momentum), while valuation signals are limited by negative earnings and no dividend.
Positive Factors
Accelerating Revenue Growth
Material revenue acceleration in 2025 indicates strengthening commercial traction for the TSE platform across clinical and veterinary customers. Durable higher sales volumes can support scale benefits, improve operating leverage over time, and validate market adoption beyond pilot stages.
Negative Factors
Negative Gross Margin
A ~-51% gross margin in 2025 shows unit economics are currently unsustainable: production, fulfillment or pricing deficits erode value per procedure. Unless costs or pricing are structurally improved, negative gross margins will prevent operating leverage and long-term profitability despite revenue growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Accelerating Revenue Growth
Material revenue acceleration in 2025 indicates strengthening commercial traction for the TSE platform across clinical and veterinary customers. Durable higher sales volumes can support scale benefits, improve operating leverage over time, and validate market adoption beyond pilot stages.
Read all positive factors
Scandinavian ChemoTech AB Class B (CMOTEC.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr99.53M
Dividend YieldN/A
Average Volume (3M)54.14K
Price to Earnings (P/E)―
Beta (1Y)-0.58
Revenue Growth87.10%
EPS Growth45.96%
CountrySE
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.10
Shares Outstanding23,802,313
10 Day Avg. Volume61,695
30 Day Avg. Volume54,140
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)37.86
Price to Sales (P/S)9.82
P/FCF Ratio-28.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr21.20M
Scandinavian ChemoTech AB Class B Business Overview & Revenue Model
Company Description
Scandinavian ChemoTech AB (publ) provides cancer care and pain management solutions. Its product, IQWave, is an electroporation device, which combines short electric pulses with chemotherapy administrated locally or intravenously used for treating...
How the Company Makes Money
ChemoTech makes money primarily by commercializing its TSE-based electroporation technology. Revenue is generated through (1) sales of medical/veterinary devices used to deliver electroporation treatments, (2) recurring sales of associated consuma...
Scandinavian ChemoTech AB Class B Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
58
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.85M | 12.29M | 6.57M | 2.82M | 473.00K | 49.00K |
| Gross Profit | 7.69M | -6.30M | 4.78M | 1.66M | -55.00K | 323.00K |
| EBITDA | -7.46M | -4.33M | -12.38M | -19.58M | -20.81M | -17.03M |
| Net Income | -10.68M | -8.06M | -13.72M | -21.09M | -22.75M | -17.74M |
Balance Sheet | ||||||
| Total Assets | 12.48M | 13.20M | 13.38M | 14.87M | 21.70M | 25.81M |
| Cash, Cash Equivalents and Short-Term Investments | 517.00K | 3.67M | 949.00K | 923.00K | 5.85M | 8.68M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 53.00K |
| Total Liabilities | 10.29M | 10.01M | 7.40M | 3.84M | 7.71M | 1.89M |
| Stockholders Equity | 2.19M | 3.19M | 5.98M | 11.03M | 13.99M | 23.92M |
Cash Flow | ||||||
| Free Cash Flow | -9.48M | -4.18M | -13.19M | -18.91M | -19.96M | -22.36M |
| Operating Cash Flow | -9.48M | -3.75M | -13.14M | -18.23M | -19.63M | -19.18M |
| Investing Cash Flow | 52.00K | -426.00K | -2.00K | -468.00K | -603.00K | -3.33M |
| Financing Cash Flow | 8.09M | 6.89M | 13.17M | 13.77M | 17.26M | 29.71M |
Scandinavian ChemoTech AB Class B Technical Analysis
Negative
4.79
Price Trends
3.64
Positive
3.86
Negative
3.98
Negative
Market Momentum
0.03
Positive
49.54
Neutral
43.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CMOTEC.B, the sentiment is Negative. The current price of 4.79 is above the 20-day moving average (MA) of 3.81, above the 50-day MA of 3.64, and above the 200-day MA of 3.98, indicating a neutral trend. The MACD of 0.03 indicates Positive momentum. The RSI at 49.54 is Neutral, neither overbought nor oversold. The STOCH value of 43.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CMOTEC.B.
Scandinavian ChemoTech AB Class B Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | kr339.76M | 1.48 | -264.12% | ― | 154.67% | ― | |
54 Neutral | kr48.95M | -4.94 | -30.39% | 11.26% | ― | 84.53% | |
53 Neutral | kr99.53M | -14.97 | -211.04% | ― | 87.10% | 45.96% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | kr89.63M | -5.14 | -202.18% | ― | ― | -62.18% | |
43 Neutral | kr43.96M | -1.97 | ― | 8.47% | ― | ― | |
42 Neutral | kr80.40M | -1.19 | -88.65% | ― | 21.37% | 27.89% |
* Healthcare Sector Average
SE:CMOTEC.B
Scandinavian ChemoTech AB Class B
3.91
2.06
110.78%
SE:2CUREX
2cureX AB
1.95
1.25
178.97%
SE:ONCOZ
OncoZenge AB
6.38
1.91
42.57%
SE:EXPRS2
ExpreS2ion Biotech Holding AB
2.19
-4.73
-68.33%
SE:LARK
CombiGene AB
2.22
-0.20
-8.23%
SE:SPRINT
Sprint Bioscience AB
3.22
2.62
433.11%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.